RECURRENT CHRONIC MYELOGENOUS LEUKEMIA, BCR-ABL1 POSITIVE
Clinical trials for RECURRENT CHRONIC MYELOGENOUS LEUKEMIA, BCR-ABL1 POSITIVE explained in plain language.
Never miss a new study
Get alerted when new RECURRENT CHRONIC MYELOGENOUS LEUKEMIA, BCR-ABL1 POSITIVE trials appear
Sign up with your email to follow new studies for RECURRENT CHRONIC MYELOGENOUS LEUKEMIA, BCR-ABL1 POSITIVE, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
New hope for CML patients: ponatinib trial targets Drug-Resistant leukemia
Disease control Recruiting nowThis study tests the drug ponatinib in people with chronic myeloid leukemia (CML) whose cancer did not respond to or who could not tolerate other targeted therapies. The goal is to see if ponatinib can control the disease by blocking a protein that helps cancer cells grow. About …
Matched conditions: RECURRENT CHRONIC MYELOGENOUS LEUKEMIA, BCR-ABL1 POSITIVE
Phase: PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated May 26, 2026 11:47 UTC
-
New drug cocktail shows promise for tough blood cancers
Disease control Recruiting nowThis study tests a combination of four chemotherapy drugs (cladribine, idarubicin, cytarabine, and venetoclax) in about 500 adults with acute myeloid leukemia, high-risk myelodysplastic syndrome, or blast-phase chronic myeloid leukemia. The goal is to see how well these drugs kil…
Matched conditions: RECURRENT CHRONIC MYELOGENOUS LEUKEMIA, BCR-ABL1 POSITIVE
Phase: PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated May 26, 2026 11:08 UTC
-
Metal detox may boost chemo in tough blood cancers
Disease control Recruiting nowThis early-stage study tests whether drugs that remove extra metals from the body can help people with acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS) respond better to chemotherapy. Researchers want to find the safest dose and see if lowering metal levels in blood…
Matched conditions: RECURRENT CHRONIC MYELOGENOUS LEUKEMIA, BCR-ABL1 POSITIVE
Phase: PHASE1 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated May 22, 2026 13:51 UTC